Mereo BioPharma (MREO) - רווח נקי למניה (EPS TTM)

Mereo BioPharma is scaling the development of orphan drugs through strategic alliances, while the TTM earnings per share chart on GURU.Markets shows that this metric equals -0.17. Business growth relies on the automation of substance synthesis with physician-monitored testing, and medium-term potential is driven by the expected results of the final phase trials for its drug treating osteogenesis imperfecta.

The development of orphan drugs by Mereo BioPharma (MREO) possesses exceptional macro-resilience, as demand for specialized therapies remains independent of economic cycles and seasonality. The earnings per share trend over the last four quarters reflects the ultimate efficiency of capital management, allowing investors to assess the real profitability of the business per share and forecast the stability of the asset's market capitalization.